9Alexander V M,Landsman P B,Teutsch S M,et al.NCEP defined metabolic syndrome diabetes and prevalence of coronary heart disease among NHANESⅢ participants age 50 years and older[J].Diabetes,2003,52(5):1210.
3Libby P. Inflammation in atherosclerosis[J]. Nature, 2002, 420(6917): 868-874.
4Fichtlscherer S, Heeschen C, Zeiher A M. Inflammatory markers and coronary artery disease[J]. Curr Opin Pharmacol, 2004, 4(12):124-131.
5Tousoulis D, Antoniades C, Nikolopoulou A, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes[J]. Eur J Clin Invest, 2007, 37(8): 623-628.
6Wang J, Zhang S, Jin Y, et al. Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome[J]. Int J Cardiol, 2007, 115(3): 361-365.
7Derosa G, D’Angelo A, Scalise F, et al. Comparison between metalloproteinases-2 and-9 in healthy subjects, diabetics, and subjects with acute coronary syndrome[J]. Heart Vessels, 2007, 22(6):361-370.
8Shu J, Ren N, Du J B, et al. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome[J]. Scand Cardiovasc J, 2007, 41(3): 149-154.
9Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris[J]. Am J Cardiol, 2006, 97(2): 175-180.
10Tan J, Hua Q, Gao J, et al. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction[J]. Clin Cardiol, 2008, 31(9): 413-418.
